Yahoo
NSE - Delayed Quote INR

Abbott India Limited (ABBOTINDIA.NS)

25,750.00 -395.00 (-1.51%)
At close: October 30 at 3:29:52 PM GMT+5:30
Chart Range Bar
Loading chart for ABBOTINDIA.NS
  • Previous Close 26,145.00
  • Open 26,005.00
  • Bid --
  • Ask --
  • Day's Range 25,555.00 - 26,455.00
  • 52 Week Range 24,650.00 - 30,655.00
  • Volume 8,621
  • Avg. Volume 7,747
  • Market Cap (intraday) 547.17B
  • Beta (5Y Monthly) 0.06
  • PE Ratio (TTM) 33.89
  • EPS (TTM) 759.85
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield 525.00 (2.05%)
  • Ex-Dividend Date Jul 24, 2026
  • 1y Target Est 32,467.38

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, hypothyroidism, central nervous system, vaccines, and multispecialty, including insomnia, vertigo, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.

www.abbott.co.in

3,679

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

ABBOTINDIA.NS
9.21%
S&P BSE SENSEX (^BSESN)
12.63%

1-Year Return

ABBOTINDIA.NS
10.97%
S&P BSE SENSEX (^BSESN)
11.78%

3-Year Return

ABBOTINDIA.NS
20.57%
S&P BSE SENSEX (^BSESN)
16.14%

5-Year Return

ABBOTINDIA.NS
38.94%
S&P BSE SENSEX (^BSESN)
25.55%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 18.14B
Earnings 4.29B
Profit Margin 23.63%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
5B
10B
15B
22.0%
22.5%
23.0%
23.5%

Analyst Insights

View More

Analyst Price Targets

29,900.00
32,467.38 Average
25,750.00 Current
38,100.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    23.05%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    70.04B

  • Net Income Avi to Common (ttm)

    16.15B

  • Diluted EPS (ttm)

    759.85

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    22.32B

  • Total Debt/Equity (mrq)

    3.60%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: